Reaxys® Medicinal Chemistry Provided as Part of Elsevier's Suite of Life
Science Solutions Delivers High Quality Content to Improve Drug Discovery and
AMSTERDAM, February 4, 2013
AMSTERDAM, February 4, 2013 /PRNewswire/ --
Comprehensive, referenced and well-structured data allows users to increase
speed and accuracy of decision making in the drug development process
Elsevier , a world-leading provider of scientific, technical and medical
information products and services, today announced the launch of Reaxys
Medicinal Chemistry. It offers medicinal chemists access to comprehensive,
referenced and well-structured data to enhance the compound selection process
across discovery and pre-clinical stages in drug research and development.
Reaxys Medicinal Chemistry will significantly improve the efficiency and
productivity of researchers engaged in the process of designing compounds and
optimizing their compatibility with one or more targets in order to
successfully treat a disease.
Dr. Juergen Swienty-Busch, Product Lead for the Reaxys suite at Elsevier,
said, "The greatest challenge of medicinal chemistry is to reduce the number
of drug candidates that fail in late stages, significantly increasing the cost
of bringing a drug to market. The well-known mantra 'fail early, fail cheap'
is now central to the drug discovery process, with much of the responsibility
borne by medicinal chemists."
Medicinal chemists develop strategies to find new drugs and to improve not
only the efficacy of compounds but also selectivity, ADME properties and
safety end-points. To support these strategies, medicinal chemists need to
have access to up-to-date, well organized and high-quality experimental data
on druggable targets, pharmacological effects, biological data points, and
ADME properties associated with chemical compounds.
Reaxys Medicinal Chemistry sources its data from a vast repository of
peer-reviewed journal articles, patents and regulatory information,
encompassing millions of compounds and associated biological data linked to
thousands of druggable proteins. It brings this information together into a
single, easily searchable solution that gives pharmaceutical companies access
to comparative data.
Reaxys Medicinal Chemistry can be used in conjunction with Elsevier's suite of
life science products; including Reaxys, the leading chemistry discovery
engine, and PharmaPendium, which focuses on regulatory approvals and drug
safety. This solution effectively brings together lead identification,
confirmation and drug repurposing.
Reaxys® is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys® combines reaction and substance
data in organic, organometallic, inorganic and physical chemistry with
synthesis planning. Researchers can get the information they need in a single
overview, from source publications carefully selected for their importance and
relevance to research chemists. Elsevier continues to engage with the
chemistry community to ensure that Reaxys® continues to reflect how chemists
think and work. For more information please visit
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier
Properties SA and used under license.
About Elsevier Elsevier is a world-leading provider of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet and Cell , and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier's
online solutions include ScienceDirect , Scopus , Reaxys , ClinicalKey and
Mosby's Nursing Suite , which enhance the productivity of science and health
professionals, and the SciVal suite and MEDai's Pinpoint Review , which help
research and health care institutions deliver better outcomes more
A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC , a world-leading
provider of professional information solutions in the Science, Medical, Legal
and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and
Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Harald Boersma Director, Corporate Relations Elsevier
Press spacebar to pause and continue. Press esc to stop.